Gentian Diagnostics YTD swings to net loss of NOK 8.5 million; YTD sales rise 11% to NOK 144.8 million

Bitget2026/10/20 06:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gentian Diagnostics swung to a year-to-date net loss of NOK 8.5 million; results included a NOK 30.2 million impairment.
Third-quarter sales rose 22% year over year to NOK 51.1 million.
Operating cash flow climbed 67% year over year to NOK 14.9 million in the third quarter.
An assay for a key IVD partner advanced from research to development, while development work with Essange Reagents started.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gentian Diagnostics ASA published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gentian Diagnostics YTD swings to net loss of NOK 8.5 million; YTD sales rise 11% to NOK 144.8 million

You may also like

Crypto prices